1. A method of preventing hypoglycemia associated with a plasma glucose concentration below 60 mg / dl in type 2 diabetes mellitus, comprising administering (a) desProExendin-4 (1-39) -Lys-NHi / or a pharmaceutically acceptable salt thereof, and ( b) metformin and / or a pharmaceutically acceptable salt thereof in need of this subject, wherein the subject to be treated has an HbA value of at least 8% .2. The method according to claim 1, wherein desProExendin-4 (1-39) -Lys-NH is administered by a single injection per day. The method of claim 1, wherein desProExendin-4 (1-39) -Lys-NHi / or a pharmaceutically acceptable salt thereof is administered subcutaneously. The method of claim 1, wherein metformin is administered orally. The method according to claim 1, wherein desProExendin-4 (1-39) -Lys-NHi / or a pharmaceutically acceptable salt is administered as an adjunct therapy to the administration of metformin. The method of claim 1, wherein the subject to be treated is obese. The method of claim 6, wherein the subject has a body mass index of at least 30.8. The method of claim 1, wherein the subject to be treated is an adult subject. The method of claim 1, wherein type 2 diabetes mellitus is not properly regulated by metformin alone. The method of claim 9, wherein treating with a dose of at least 1.5 g / day of one metformin for three months does not properly regulate type 2 diabetes. The method of claim 1, wherein the subject to be treated has a HbA value of up to 10%. The method of claim 1, wherein the hypoglycemia is associated with a plasma glucose concentration below 50 mg / dl, below 40 mg / dl, or below 36 mg / dl. The method of claim 1, wherein the hypoglycemia is symptomatic hypoglycemia. The method of claim 13, wherein symptomatic hypoglycemia is associated with at least one symptom1. Способ предотвращения гипогликемии, связанной с концентрацией глюкозы в плазме ниже 60 мг/дл, при сахарном диабете 2 типа, включающий введение(a) desProЭксендин-4(1-39)-Lys-NHи
